We further examined the functional effect of GNL3L in colon cancer cells in vivo by subcutaneously injecting LoVo cells pretreated with a predesigned GNL3L silencer that is activated in vivo, and the systemic delivery of predesigned siRNA was performed thrice with one-week intervals. Here, GNL3L is linked to colonic neoplasm.